• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Forma Therapeutics to Present at the Jefferies Healthcare Conference

    6/3/22 7:05:00 AM ET
    $FMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FMTX alert in real time by email

    Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will participate in the Jefferies Healthcare Conference taking place June 8-10, 2022. Forma will present on June 9, 2022 at 2:00 p.m. Eastern Daylight Time (EDT).

    A webcast of the conference presentation will be available in the "News & Investors" section of Forma's website at www.FormaTherapeutics.com.

    About Forma Therapeutics

    Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005071/en/

    Get the next $FMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FMTX

    DatePrice TargetRatingAnalyst
    6/13/2022$46.00 → $21.00Overweight
    Cantor Fitzgerald
    11/12/2021$54.00 → $40.00Outperform
    SVB Leerink
    8/17/2021$55.00 → $53.00Buy
    HC Wainwright & Co.
    8/2/2021$58.00Buy
    Craig Hallum
    More analyst ratings